Celularity (NASDAQ:CELUW) and Caribou Biosciences (NASDAQ:CRBU) Critical Comparison

Celularity (NASDAQ:CELUW) and Caribou Biosciences (NASDAQ:CRBU) are both healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their profitability, valuation, risk, institutional ownership, earnings, analyst recommendations and dividends.

Earnings & Valuation

This table compares Celularity and Caribou Biosciences”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Celularity	$26.55 million	N/A	N/A	N/A	N/A
Caribou Biosciences	$11.16 million	15.95	-$148.12 million	($1.08)	-1.54

Celularity has higher revenue and earnings than Caribou Biosciences.

Profitability

This table compares Celularity and Caribou Biosciences’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Celularity	N/A	N/A	N/A
Caribou Biosciences	-1,030.42%	-89.11%	-62.47%

Analyst Recommendations

This is a breakdown of recent ratings and recommmendations for Celularity and Caribou Biosciences, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Celularity	0	0	0	0	0.00
Caribou Biosciences	1	0	3	1	2.80

Caribou Biosciences has a consensus target price of $7.75, suggesting a potential upside of 366.87%. Given Caribou Biosciences’ stronger consensus rating and higher probable upside, analysts clearly believe Caribou Biosciences is more favorable than Celularity.

Institutional & Insider Ownership

77.5% of Caribou Biosciences shares are owned by institutional investors. 8.5% of Caribou Biosciences shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Summary

Caribou Biosciences beats Celularity on 6 of the 10 factors compared between the two stocks.

About Celularity

Celularity Inc., a clinical-stage biotechnology company, develops off-the-shelf placental-derived allogeneic cell therapies for the treatment of cancer, immune, and infectious diseases. It operates through three segments: Cell Therapy, Degenerative Disease, and BioBanking. The company's lead therapeutic programs include CYCART-19, an allogeneic CAR-T cell for the treatment of non-Hodkin's lymphoma (NHL) and mantle cell lymphoma (MCL); CYNK-001, an allogeneic unmodified natural killer cell that is in Phase I/II clinical trial for the treatment of acute myeloid leukemia (AML); and APPL-001, a genetically modified placental-derived mesenchymal-like adherent stromal cell for the treatment of Crohn's disease. It is also developing CYCART-201 for the treatment of NHL and MCL, and human epidermal growth factor receptor 2 positive cancers; CYNK-301, a next generation chimeric antigen receptor-natural killer (CAR-NK) for treating relapse refractory AML; CYNK-302, a CAR-NK to treat non-small cell lung cancer; and pExo-001, a human postpartum placenta derived exosome product for the treatment of osteoarthritis. It also produces, sells, and licenses products that are used in surgical and wound care markets, such as Biovance, Biovance 3L, Interfyl, and Centaflex; and collects and stores stem cells from umbilical cords and placentas under the LifebankUSA brand. The company has licensing agreement with Sorrento Therapeutics, Inc. for the development and commercialization of licensed CD19 CAR-T products; and research collaboration services agreement with Regeneron Pharmaceuticals, Inc. to support the research of allogeneic cell therapy candidates. The company was founded in 1998 and is based in Florham Park, New Jersey.

About Caribou Biosciences

Caribou Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of genome-edited allogeneic cell therapies for the treatment of hematologic malignancies in the United States and internationally. Its lead product candidate is CB-010, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1 clinical trial to treat relapsed or refractory B cell non-Hodgkin lymphoma. The company also develops CB-011, an allogeneic anti-BCMA CAR-T cell therapy that is in phase 1 clinical trial for the treatment of relapsed or refractory multiple myeloma; and CB-012, an allogeneic anti-CD371 CAR-T cell therapy that is in phase 1 clinical trial for the treatment of relapsed or refractory acute myeloid leukemia. Caribou Biosciences, Inc. was incorporated in 2011 and is headquartered in Berkeley, California.